Literature DB >> 11979140

Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin.

Devang N Prajapati1, Julianne R Newcomer, Jeanne Emmons, Majed Abu-Hajir, David G Binion.   

Abstract

Recent reports suggest that unfractionated heparin may be a useful adjunct in the treatment of inflammatory bowel disease (IBD). We report the successful use of subcutaneous unfractionated heparin to treat a moderate-to-severe flare of Crohn's disease during pregnancy, which was refractory to standard therapy. The patient received 10,000 units of unfractionated heparin subcutaneously twice a day after her Crohn's colitis failed to come under remission with intravenous corticosteroids. Heparin was continued throughout her pregnancy. Following initiation of adjunctive heparin therapy, the patient experienced a rapid clinical response, was able to discontinue intravenous steroids, discharge from the hospital, and ultimately deliver a healthy term newborn. Although there is extensive obstetric experience with heparin in the treatment of thrombosis associated with pregnancy, there is limited information regarding its use in IBD patients during pregnancy. Because heparin has an established track record in maternal-fetal medicine, this agent may be considered in women who suffer an inflammatory flare of IBD during pregnancy who have not responded to standard treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979140     DOI: 10.1097/00054725-200205000-00006

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.

Authors:  Sheng-Li Ji; Hui-Fei Cui; Feng Shi; Yan-Qing Chi; Ji-Chao Cao; Mei-Yu Geng; Hua-Shi Guan
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

3.  Inflammatory bowel disease in pregnancy.

Authors:  E M Alstead; C Nelson-Piercy
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

4.  Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration.

Authors:  L M Hiebert; T Ping; S M Wice
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

Review 5.  Possible immunosuppressive effects of drug exposure and environmental and nutritional effects on infection and vaccination.

Authors:  H P Huemer
Journal:  Mediators Inflamm       Date:  2015-04-05       Impact factor: 4.711

6.  Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1β and inhibiting syndecan-1 shedding in the intestinal mucosa.

Authors:  Xian-fei Wang; Ai-ming Li; Jing Li; Shi-yong Lin; Chu-di Chen; You-Lian Zhou; Xia Wang; Cun-long Chen; Si-de Liu; Ye Chen
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

7.  Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.

Authors:  Jean-Paul Motta; Simone Palese; Carmine Giorgio; Kevin Chapman; Alexandre Denadai-Souza; Perrine Rousset; David Sagnat; Laura Guiraud; Anissa Edir; Carine Seguy; Laurent Alric; Delphine Bonnet; Barbara Bournet; Louis Buscail; Cyrielle Gilletta; Andre G Buret; John L Wallace; Morley D Hollenberg; Eric Oswald; Elisabetta Barocelli; Sylvie Le Grand; Bruno Le Grand; Celine Deraison; Nathalie Vergnolle
Journal:  J Crohns Colitis       Date:  2021-05-04       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.